Unlocking the Potential of Medical Cannabis
A New Era of Marijuana Research
Retired Prison Governor, Vanessa Frake-Harris MBE and Consultant Neurologist, Mike Barnes, debate whether Britain should legalise cannabis.
Listen To What Doctors Say
Time 4 Hemp hosted a segment about the history of medical cannabis research with Al Byrne, Dr. Donald Abrams, Dr. Ethan Russo, Dr. Denis Petro, Dr. Raphael Mechoulam, Dr. Andrew Weil and Mary Lynn Mathre.
Click here to listen to this very special segment.
New Studies Of The Global Medical Cannabis Market
Written by Casper Leitch
Medical cannabis, heralded as a potential treatment for various health conditions, remains a subject of great interest and debate. While its use is legal in many states, there's still much we don't know about its effectiveness as a therapy.
However, a groundbreaking initiative known as the National Cannabis Study aims to shed light on this topic by tracking the experiences of approximately 10,000 patients undergoing cannabis treatment. This study, part of the broader Cannabis and Health Research Initiative, seeks to address the lack of comprehensive data surrounding medical cannabis.
Led by the Johns Hopkins Bloomberg School of Public Health and funded by a generous $10 million grant from the National Institute on Drug Abuse, this research endeavor holds immense promise. Collaborating with experts from organizations like Realm of Caring, the study will follow patients as they embark on their medical cannabis journey, from initial use to long-term treatment.
The goal? To understand the health impacts of therapeutic cannabis use and provide valuable insights into which products may offer the most benefit for specific conditions. By collecting data on variables such as product composition, delivery methods, and dosage, researchers hope to tailor treatment recommendations to individual needs.
One key aspect of the study is its focus on patient experiences. Through regular assessments and feedback, researchers aim to capture the real-world challenges and successes of medical cannabis users. This patient-centered approach ensures that findings are relevant and meaningful to those who stand to benefit from them the most.
Moreover, the data collected will not only inform clinical decision-making but also contribute to the development of policies, regulatory frameworks, and future research endeavors. By fostering a deeper understanding of medical cannabis, this initiative paves the way for advancements in treatment options and patient care.
In a landscape where hundreds of cannabis products exist, each with its own unique properties, narrowing the focus of research is essential. By identifying areas of promise and directing scientific efforts accordingly, we can maximize the potential of medical cannabis as a safe and effective therapy.
With the National Cannabis Study leading the way, we're entering a new era of discovery and innovation in the field of medical cannabis. We are learning more about how to unlock the full potential of this remarkable plant and improve the lives of countless individuals in need.
Breakthroughs In Medical Cannabis Healthcare
Exciting developments are on the horizon for the medical cannabis industry. With recent breakthroughs in research and recommendations for policy changes, there's a growing momentum towards unlocking the full potential of cannabis in healthcare.
A recent study identified an impressive 65 potential biomarkers that respond to cannabis, signaling a promising future for medical applications. Moreover, the US Department of Health and Human Services has recommended rescheduling cannabis, marking a significant shift in attitudes towards its therapeutic value.
In this dynamic landscape, 'The Pharmaceutical Cannabis Report: 3rd Edition' emerges as a beacon of insight. This comprehensive report offers a deep dive into the world of pharmaceutical cannabis, providing valuable analysis for entrepreneurs and industry leaders.
One of the report's highlights is its market forecast, projecting substantial growth in the global pharmaceutical cannabis industry from 2023 to 2027. With sales expected to reach $1.37 billion by 2027, businesses need to stay informed to capitalize on emerging opportunities.
Key players like Epidiolex, Dronabinol, and Sativex dominate the market, with Epidiolex projected to hold a staggering 76% market share in 2023. However, the industry is diverse, with various treatments contributing to its expansion.
As interest in cannabinoid-based therapies continues to rise, Jazz Pharmaceuticals emerges as a leading patent holder in this space. CBD and THC remain at the forefront of innovation, underlining their significance in medical cannabis research.
Understanding the financial landscape is essential for businesses navigating this evolving industry. With insights into the costs of clinical trials and market dynamics, the report equips decision-makers with the knowledge needed to make strategic investments.
Geographically, North America and Europe emerge as key markets for pharmaceutical cannabis sales. By analyzing sales patterns and target regions, businesses can identify lucrative opportunities for expansion.
In addition to the market forecast, the report provides a detailed assessment of key cannabinoid treatments, including Epidiolex, Dronabinol, and Sativex. While other treatments contribute minimally to global sales, they play a role in shaping the industry's landscape.
In a rapidly evolving industry, knowledge is power. 'The Pharmaceutical Cannabis Report: 3rd Edition' empowers businesses to navigate complexities and capitalize on emerging trends. By staying informed, industry leaders can drive innovation and unlock the full potential of medical cannabis.
Below is a FREE TO DOWNLOAD marijuana music MP3 by Israel Vibration.
Herb Is The Healing Of The Nation
The New England Journal of Medicine has revealed new benefits of medicinal cannabis in treating children with epilepsy, cancer patients and seniors. Surgeon and neuroscientist Rahul Jandial discuss what it could mean for the future of medicine.
